RCUS
Arcus Biosciences Inc
NYSE: RCUS · HEALTHCARE · BIOTECHNOLOGY
$24.13
-2.70% today
Updated 2026-04-29
Market cap
$3.03B
P/E ratio
—
P/S ratio
12.27x
EPS (TTM)
$-3.29
Dividend yield
—
52W range
$7 – $29
Volume
1.3M
WallStSmart proprietary scores
30
out of 100
Grade: F
Strong Sell
Investment rating
7.3
Growth
B+6.0
Quality
B2.0
Profitability
F6.7
Valuation
B1/9
Piotroski F-Score
Weak
-0.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$34.00
+40.90%
12-Month target
—
—
Intrinsic (DCF)
$184.95
Margin of safety
+88.45%
0 Strong Buy9 Buy3 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Revenue growth 26.90% QoQ
+ 88.45% below intrinsic value
+ Debt/equity 0.25x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -0.89 — distress zone
- Thin margins at -142.90%
- Negative free cash flow $-121.00M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $112.00M | $117.00M | $258.00M | $247.00M | $247.00M |
| Net income | $-267.00M | $-307.00M | $-283.00M | $-353.00M | $-98.00M |
| EPS | — | — | — | — | $-3.29 |
| Free cash flow | $432.00M | $-330.00M | $-176.00M | $-484.00M | $-121.00M |
| Profit margin | -238.39% | -262.39% | -109.69% | -142.91% | -142.90% |
Peer comparison
Smart narrative
Arcus Biosciences Inc trades at $24.13. Our Smart Value Score of 30/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -0.89, it sits in the distress. TTM revenue stands at $247.00M. with profit margins at -142.90%. Our DCF model estimates intrinsic value at $184.95.
Frequently asked questions
What is Arcus Biosciences Inc's stock price?
Arcus Biosciences Inc (RCUS) trades at $24.13.
Is Arcus Biosciences Inc overvalued?
Smart Value Score 30/100 (Grade F, Strong Sell). DCF value $184.95.
What is the price target of Arcus Biosciences Inc (RCUS)?
The analyst target price is $34.00, representing +40.9% upside from the current price of $24.13.
What is the intrinsic value of Arcus Biosciences Inc (RCUS)?
Based on our DCF model, intrinsic value is $184.95, a +88.5% margin of safety versus $24.13.
What is Arcus Biosciences Inc's revenue?
TTM revenue is $247.00M.
Piotroski F-Score?
1/9 — weak financial health.
Altman Z-Score?
-0.89 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio12.27x
ROE-63.30%
Beta0.86
50D MA$22.37
200D MA$18.41
Shares out0.13B
Float0.09B
Short ratio—
Avg volume1.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—